Teleflex (TFX) to Release Earnings on Thursday

Teleflex (NYSE:TFX) is scheduled to be announcing its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $3.07 per share for the quarter. Teleflex has set its FY 2024 guidance at 13.550-13.950 EPS and its FY24 guidance at $13.55-$13.95 EPS.Parties interested in registering for the company’s conference call can do so using this link.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 22nd. The medical technology company reported $3.38 EPS for the quarter, topping the consensus estimate of $3.26 by $0.12. Teleflex had a return on equity of 14.98% and a net margin of 11.98%. The company had revenue of $773.90 million during the quarter, compared to analyst estimates of $769.01 million. During the same period in the previous year, the business earned $3.52 EPS. Teleflex’s quarterly revenue was up 2.1% on a year-over-year basis. On average, analysts expect Teleflex to post $14 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Teleflex Stock Performance

NYSE TFX opened at $208.48 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.32 and a quick ratio of 1.29. The stock’s 50 day simple moving average is $220.38 and its 200-day simple moving average is $226.18. The company has a market cap of $9.82 billion, a PE ratio of 27.69, a price-to-earnings-growth ratio of 1.98 and a beta of 1.11. Teleflex has a 1-year low of $177.63 and a 1-year high of $276.43.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were issued a $0.34 dividend. The ex-dividend date was Thursday, February 29th. This represents a $1.36 dividend on an annualized basis and a yield of 0.65%. Teleflex’s payout ratio is currently 18.06%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on TFX shares. Truist Financial dropped their target price on shares of Teleflex from $270.00 to $265.00 and set a “hold” rating for the company in a report on Friday, February 23rd. JMP Securities reaffirmed a “market outperform” rating and set a $285.00 price objective on shares of Teleflex in a research note on Friday, February 23rd. Royal Bank of Canada decreased their target price on shares of Teleflex from $272.00 to $265.00 and set an “outperform” rating on the stock in a research note on Friday, February 23rd. Finally, StockNews.com cut Teleflex from a “buy” rating to a “hold” rating in a report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Teleflex presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.50.

Insider Transactions at Teleflex

In other news, VP Cameron P. Hicks sold 7,401 shares of Teleflex stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the sale, the vice president now owns 10,050 shares of the company’s stock, valued at approximately $2,261,250. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.43% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.